Warning Letter — BlephEx, LLC
The FDA issued a warning letter to BlephEx, LLC following an inspection by the Center for Devices and Radiological Health (CDRH). The source indicates that the regulatory action is based on compliance issues identified during this oversight process.
BlephEx, LLC, and medical device manufacturers involved in the production and marketing of specialized ophthalmic devices and tools. It specifically impacts regulatory affairs and quality assurance professionals responsible for device labeling and cleared indications.
The issuance of a Warning Letter by CDRH typically indicates that a firm has failed to adequately address observations from a prior inspection, such as Form 483 findings. This suggests that the company's quality management system or regulatory submissions may be insufficient to support their current operations. For the wider industry, this signals continued FDA scrutiny regarding the alignment between cleared device indications and actual marketing claims or manufacturing processes.
QA and Regulatory departments should review all existing marketing and training materials to ensure that current claims do not exceed the scope of the device's original 510(k) clearance or PMA. Compliance teams should conduct an internal audit of labeling to verify that high-risk or invasive indications have not been added without supplemental FDA submission.
FDA Warning Letter issued to: BlephEx, LLC. 06/03/2026 — Center for Devices and Radiological Health. Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/blephex-llc-725861-06032026
Open in openFDA / FDA.gov